Immunotherapy of cancer tumors with inhibition of PD-1 membrane protein and its ligands interaction

The identification of the PD-1 receptor by Tasuku Honjo and CTLA-4 by James Ellison marked the beginning of the study of new regulatory pathways activating the immune response. The term “immune checkpoints” was introduced to denote the system of inhibitory mechanisms that include these proteins. The...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	A. V. Chetveryakov, V. L. Tsepelev
Formato:	article
Lenguaje:	RU
Publicado:	Scientific Сentre for Family Health and Human Reproduction Problems 2021
Materias:	immunity tumor immunotherapy pd-1 immune control points Science Q
Acceso en línea:	https://doaj.org/article/ea6c4a1bb2ae4dbe9e16de4c96530ab5
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:ea6c4a1bb2ae4dbe9e16de4c96530ab5
record_format	dspace
spelling	oai:doaj.org-article:ea6c4a1bb2ae4dbe9e16de4c96530ab52021-11-23T06:14:46ZImmunotherapy of cancer tumors with inhibition of PD-1 membrane protein and its ligands interaction2541-94202587-959610.29413/ABS.2021-6.4.13https://doaj.org/article/ea6c4a1bb2ae4dbe9e16de4c96530ab52021-10-01T00:00:00Zhttps://www.actabiomedica.ru/jour/article/view/2982https://doaj.org/toc/2541-9420https://doaj.org/toc/2587-9596The identification of the PD-1 receptor by Tasuku Honjo and CTLA-4 by James Ellison marked the beginning of the study of new regulatory pathways activating the immune response. The term “immune checkpoints” was introduced to denote the system of inhibitory mechanisms that include these proteins. The review presents the literature data on the molecular characteristics of the membrane protein PD-1 (programmed cell death 1 receptor) and its role in the regulation of immunity. We consider the PD-1 pathways used of by tumor cells to escape the immune response. The discovery of immune checkpoints made it possible to develop a new type of targeting therapy for cancer. The review presents the results of clinical trials of drugs that block the interaction between the PD-1 and its ligands in various types of cancer. These drugs include nivolumab, pembrolizumab, and avelumab. Studies of these drugs efficacy in patients with various types of cancer localization were conducted within the CheckMate, KEYNOTE and JAVELIN Solid Tumor programs, with some research being in progress. We analyze the results of studying the clinical efficacy of the drugs in patients with melanoma, lung cancer, renal cell cancer, colorectal cancer, classical Hodgkin’s lymphoma, Merkel carcinoma and stomach cancer. Both positive and inconclusive results in the treatment of patients are noted. These data made it possible to identify promising directions for the use of the drugs in certain localizations of the malignant process, as well as to determine the dose and time of their use to obtain an objective positive response to treatment.A. V. ChetveryakovV. L. TsepelevScientific Сentre for Family Health and Human Reproduction Problemsarticleimmunitytumor immunotherapypd-1immune control pointsScienceQRUActa Biomedica Scientifica, Vol 6, Iss 4, Pp 146-159 (2021)
institution	DOAJ
collection	DOAJ
language	RU
topic	immunity tumor immunotherapy pd-1 immune control points Science Q
spellingShingle	immunity tumor immunotherapy pd-1 immune control points Science Q A. V. Chetveryakov V. L. Tsepelev Immunotherapy of cancer tumors with inhibition of PD-1 membrane protein and its ligands interaction
description	The identification of the PD-1 receptor by Tasuku Honjo and CTLA-4 by James Ellison marked the beginning of the study of new regulatory pathways activating the immune response. The term “immune checkpoints” was introduced to denote the system of inhibitory mechanisms that include these proteins. The review presents the literature data on the molecular characteristics of the membrane protein PD-1 (programmed cell death 1 receptor) and its role in the regulation of immunity. We consider the PD-1 pathways used of by tumor cells to escape the immune response. The discovery of immune checkpoints made it possible to develop a new type of targeting therapy for cancer. The review presents the results of clinical trials of drugs that block the interaction between the PD-1 and its ligands in various types of cancer. These drugs include nivolumab, pembrolizumab, and avelumab. Studies of these drugs efficacy in patients with various types of cancer localization were conducted within the CheckMate, KEYNOTE and JAVELIN Solid Tumor programs, with some research being in progress. We analyze the results of studying the clinical efficacy of the drugs in patients with melanoma, lung cancer, renal cell cancer, colorectal cancer, classical Hodgkin’s lymphoma, Merkel carcinoma and stomach cancer. Both positive and inconclusive results in the treatment of patients are noted. These data made it possible to identify promising directions for the use of the drugs in certain localizations of the malignant process, as well as to determine the dose and time of their use to obtain an objective positive response to treatment.
format	article
author	A. V. Chetveryakov V. L. Tsepelev
author_facet	A. V. Chetveryakov V. L. Tsepelev
author_sort	A. V. Chetveryakov
title	Immunotherapy of cancer tumors with inhibition of PD-1 membrane protein and its ligands interaction
title_short	Immunotherapy of cancer tumors with inhibition of PD-1 membrane protein and its ligands interaction
title_full	Immunotherapy of cancer tumors with inhibition of PD-1 membrane protein and its ligands interaction
title_fullStr	Immunotherapy of cancer tumors with inhibition of PD-1 membrane protein and its ligands interaction
title_full_unstemmed	Immunotherapy of cancer tumors with inhibition of PD-1 membrane protein and its ligands interaction
title_sort	immunotherapy of cancer tumors with inhibition of pd-1 membrane protein and its ligands interaction
publisher	Scientific Сentre for Family Health and Human Reproduction Problems
publishDate	2021
url	https://doaj.org/article/ea6c4a1bb2ae4dbe9e16de4c96530ab5
work_keys_str_mv	AT avchetveryakov immunotherapyofcancertumorswithinhibitionofpd1membraneproteinanditsligandsinteraction AT vltsepelev immunotherapyofcancertumorswithinhibitionofpd1membraneproteinanditsligandsinteraction
_version_	1718416917569470464

Immunotherapy of cancer tumors with inhibition of PD-1 membrane protein and its ligands interaction

Ejemplares similares